Direct measurement of growth hormone (GH) in problems of disordered growth has revealed conditions in which growth is poor despite the presence of GH levels which are normal to elevated (1). Studies of the potential involvement of the insulin-like growth factors/somatomedins (IGFs) in these GH-resistant states have indicated (a) that there is regulation of IGF generation by factors other than GH, and (b) that there is regulation of IGF action by other circulating factors, the IGF inhibitors. In malnutrition, diabetes, glucocorticoid excess, and renal failure, GH-resistant growth failure is associated with low circulating levels of IGF activity as measured by cartilage bioassay (Table 1).
KeywordsSulfate Uptake Glucocorticoid Excess Size Exclusion HPLC Somatomedin Activity Hepatic Release
Unable to display preview. Download preview PDF.
- 8.Phillips, L.S. “Somatomedin Inhibitors” (Proceedings of the International Workshop on Advances in Research on Human Growth, Airlie, VA. (In press, 1989)Google Scholar
- 9.Van den Brande, J.L. and Du Caju, M.V.L. Plasma somatomedin activity in children with growth disturbances. In: Advances in Human Growth Hormone Research, edited by Raiti, S. Washington: DHEW, 1974, p. 98–126.Google Scholar
- 12.Goldstein, S. and Phillips, L.S. Nutrition and Somatomedin XVIII. Nutritionally-regulated release of somatomedins and somatomedin inhibitors from perfused livers in rats. Metabolism (in press, 1989)Google Scholar
- 17.Hofert, J.F., Goldstein, S. and Phillips, L.S. Glucocorticoids are required for elevation of somatomedin inhibitors in diabetic rats. Metabolism (in press, 1989)Google Scholar
- 20.Binoux, M., Lassarre, C. and Hardouin, N. Somatomedin production by rat liver in organ culture. I. Studies on the release of insulin-like growth factor and its carrier protein measured by radioligand assays. Effects of growth hormone, insulin and Cortisol. Acta Endocrinol 99:422–430, 1982PubMedGoogle Scholar
- 24.Gagliardi, A.R.T., Goldstein, S. and Phillips, L.S. Somatomedin inhibitor in diabetic rats: relation to ketogenesis and gluconeogenesis. Clin Res 36:23A, 1988 (Abstract)Google Scholar
- 25.Kelly, R.A., O’Hara, D.S., Mitch, W.E. and Smith, T.W. Identification of NaK-ATPase inhibitors in human plasma as nonesterified fatty acids and lysophospholipids. J Biol Cher. 261:11704–11711, 1986Google Scholar
- 29.Brinkman, A., Groffen, C., Kortleve, D.J., van Kessel, A.G. and Drop, S.L.S. Isolation and characterization of a cDNA encoding the low olecular weight insulin-like growth facending protein (IBP-1). EMBO 7:2417–2423, 1988Google Scholar
- 30.Lee, Y-L., Hintz, R.L., James, P.M., Lee, P.D.K., Shively, J.E. and Powell, D.R. Insulin-like growth factor (IGF) binding protein complementary deoxyribonucleic acid from human HEP G2 hepatoma cells: predicted protein sequence suggests an IGF binding domain different from those of the IGF-1 and IGF-11 receptors. Molec Endocrinol 2:404–411, 1988CrossRefGoogle Scholar